The Walt lab pioneered the microwell array-based platforms for ultrasensitive biomarker detection and is now working towards new diagnostic approaches and translating them into products that can non-invasively and more accurately diagnose and assess the states of certain forms of cancer, infectious and neurodegenerative diseases. The technique, known as Single Molecule Arrays (Simoa), utilizes a novel digital readout method and can be used to detect proteins, post-translational modifications, microRNAs and biologically relevant small molecules. Most importantly, Simoa has the ability to improve the limit of detection of conventional enzyme-linked immunosorbent assay (ELISA) by 100-1000 fold. This increased sensitivity is critical for early disease diagnostics and for detecting differences between patients and healthy subjects that may be unobservable by other technologies.
2019/01: Dr. Walt is to be inducted into the National Inventors Hall of Fame at CES as an “innovation game-changer who has transformed our world”!
2019/01: Limor, Alissa and Stacy’s work on “Impact of clinical sample handling and processing on ultra-low level measurements of plasma cytokines” was published in Clinical Biochemistry!
2018/12: Xu and Limor’s work on “Competitive Immunoassays for the Detection of Small Molecules Using Single Molecule Arrays” was published in the Journal of the American Chemical Society!
2018/11: In collaboration with Prof. George Church’s group (Wyss Institute) and Prof. Alice Chen-Plotkin (University of Pennsylvania), our lab received a grant from Chan Zuckerberg Initiative to enable better diagnosis and monitoring of Parkinson’s disease.